Loading asset research
Q3 2026 earnings · Nov 4
Royalty Pharma plc Class A Ordinary Shares
RPRXNasdaq · USD · StocksQuote as of · Exchange session not verified$58.23
+1.01%
Today
RPRX
Loading 1D prices…
Market cap
$33.6B
Volume
2M
52w high
$64.3852w low
$34.11Company profile
Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
New York, NY, United States
Employees
100
Fiscal year end
1231
CIK
1802768
Session & valuation
Open$57.69
Previous close$57.65
Day high$58.87
Day low$57.66
30-day avg. volume3M
Outstanding shares388.1M
Diluted EPS$1.78
Latest annual period
P/E (trailing)31.30
P/E (forward)10.15
Price / book3.75
Beta0.43
Dividend yield+1.61%
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals Inc. Common Stock | $34.2B | $3.7B | +8.45% | $2.33 | +3.83% | Buy |
| ZTSZoetis Inc. Class A Common Stock | $29.4B | $9.5B | +28.23% | $6.02 | -0.78% | Hold |
| ONCBeOne Medicines Ltd. American Depositary Shares | $40.8B | $5.3B | +5.37% | $0.19 | -1.38% | Buy |
| ROIVRoivant Sciences Ltd. Common Shares | $25.9B | $8.3M | -3629.19% | -$0.54 | -2.74% | Buy |
| INSMInsmed Incorporated Common Stock | $25.7B | $606.4M | -210.54% | -$6.42 | +2.71% | Buy |